Revalia Bio Raises $14.5 Million Seed Round to Advance Human Data Trials Platform for Drug Development
Revalia Bio, a biotech startup based in New Haven, Connecticut, has secured $14.5 million in a seed funding round to launch its innovative “Human Data Trials” platform. This brings the company’s total funding to $19.5 million. The round was co-led by America’s Frontier Fund and Sierra Ventures, with participation from Roger Ferguson, former Vice Chair of the U.S. Federal Reserve and a member of the Board of Directors at Alphabet.
Founded in March 2023 as a spinout from Yale University, Revalia Bio aims to revolutionize preclinical drug development by providing pharmaceutical companies with early, predictive insights from real, functional human organs. The company’s platform utilizes proprietary perfusion technology to revive and sustain human organs that are otherwise unsuitable for clinical transplant. These organs are donated with informed consent from families and are maintained under clinical conditions to enable rigorous testing.
Revalia’s approach addresses a significant challenge in drug development: the high failure rate of drug candidates due to poor translation from preclinical models to human biology. Traditional animal models and in vitro systems often fall short in predicting how therapies will behave in real patients, leading to delays, cost overruns, and failed trials. By providing access to functional human data, Revalia aims to improve the accuracy of preclinical data, reduce development costs, and eliminate risks to living patients.
Since its commercial launch in 2023, Revalia Bio has demonstrated significant growth. The company has quadrupled its revenue and recently signed two of the world’s top 10 pharmaceutical companies as customers. Additionally, Revalia has developed a first-of-its-kind human lung cancer model in partnership with LifeShare of Oklahoma and achieved key breakthroughs in organ perfusion, including a four-day kidney protocol.
The recent funding will enable Revalia Bio to further enhance its platform features, expand its market reach, and drive innovation in the field of human-centered drug development. The company’s commitment to providing a trusted, independent set of tools and recommendations ensures that organizations can maintain a hardened cybersecurity posture against sophisticated adversaries.
As the pharmaceutical industry continues to seek more accurate and reliable methods for drug development, Revalia Bio’s innovative solutions offer a promising alternative to traditional models. With the support of its investors and a clear focus on addressing the evolving challenges in drug development, Revalia Bio is well-positioned to lead the charge in human-centered drug development.
